Shots:

• SunPharma to receive upfront and milestones for licensing its product to Hikma and will supply Ilumya.  Hikma will be responsible for the registration and commercialization of the product in all MENA markets
• Hikma’s presence in the MENA region will enable access to a new treatment option for people who are unable to manage their moderate-to-severe plaque psoriasis
• Ilumya (tildrakizumab) is a humanized lgG1/k mAb designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor and has received the US FDA’s approval in 2018

Click here to read full press release/ article | Ref: Sun Pharma | Image: Pharmaworld